Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Long-Term Investments (2017 - 2021)

Insight Molecular Diagnostics' Long-Term Investments history spans 3 years, with the latest figure at $2.0 million for Q1 2021.

  • On a quarterly basis, Long-Term Investments fell 80.87% to $2.0 million in Q1 2021 year-over-year; TTM through Mar 2021 was $2.0 million, a 80.87% decrease, with the full-year FY2020 number at $13.4 million, up 506.83% from a year prior.
  • Long-Term Investments hit $2.0 million in Q1 2021 for Insight Molecular Diagnostics, down from $13.4 million in the prior quarter.
  • Over the last five years, Long-Term Investments for IMDX hit a ceiling of $14.3 million in Q2 2020 and a floor of $2.0 million in Q1 2021.
  • Historically, Long-Term Investments has averaged $7.5 million across 3 years, with a median of $6.4 million in 2019.
  • Biggest five-year swings in Long-Term Investments: skyrocketed 506.83% in 2020 and later plummeted 80.87% in 2021.
  • Tracing IMDX's Long-Term Investments over 3 years: stood at $2.2 million in 2019, then skyrocketed by 506.83% to $13.4 million in 2020, then tumbled by 84.83% to $2.0 million in 2021.
  • Business Quant data shows Long-Term Investments for IMDX at $2.0 million in Q1 2021, $13.4 million in Q4 2020, and $2.1 million in Q3 2020.